Efficacy and safety of raltegravir-based therapy in antiretroviral-naive patients with HIV-1 infection: A Meta-analysis

目的评价联合雷特格韦治疗方案用于人类免疫缺陷病毒-1 human immunodeficiency virus; 1,HIV-1)初次抗病毒治疗的安全性和有效性。方法检索联合雷特格韦用于HIV-1感染者初次抗病毒治疗的临床随机对照试验(randomized; controlled trial,RCT),采用Rev Man 5.2软件和Stata; 12.0进行Meta分析。结果纳入17个RCT,Meta分析结果:以血浆病毒载量0.05);治疗240周,试验组有效率高于对照组(70.2%和61.5%),合并效应量(RR = 1.15,95% CI: 1.03 ~; 1.28,P = 0.010)。试验组与对照组在腹泻、恶心、头晕、头痛、失眠等常见不良反应差异均无统计学意义(均有P; >0.05);其中96周及144/156周时脂质代谢异常增高合并效应量RR(95%; CI)分别低密度脂蛋白0.16(0.05~0.49)、0.20(0.08~0.48),甘油三酯0.12(0.02~; 0.59)、0.12(0.03~0.59),总胆固醇0.04(0.00~0.40)、0.04(0.00 ~; 0.34)。脂质代谢指标异常增高发生率,试验组均少于对照组,差异均有统计学意义(均有P 0.05) between the; raltegravir group and control group, proportion of patients with; virological response (plasma viral load 0.05) at weeks 48 and 96, respectively.; At weeks 96,144/156, the mean changes from baseline in LDL-cholesterol; (LDL) 0.16(0.05-0.49), 0.20 (0.08-0.48), triglyceride (TG); 0.12(0.02-0.59), 0.12(0.03-0.59) and total cholesterol (TC),; 0.04(0.00-0.40), 0.04(0.00-0.34) concen-trations, the raltegravir-based; regimens group had a lower incidence rate than the control group (all P; < 0.05). Conclusions Current evidence shows that the raltegravir-based; therapy had long-term and well tolerated antiretroviral activity, which; was non-inferior to current regimens recommended for; antiretroviral-native adults and adolescents with HIV-infection. Due to; limited quality and quantity of the included studies, more high quality; studies would be needed to verify the above conclusion.国家自然科学基金; 福建省科技创新平

HIV-1 CAP2NC蛋白的表达及体外自组装

构建并表达HIV-1 CAP2NC蛋白,探索其体外自组装条件。通过PCR技术扩增HIV-1(NL4-3毒株)CAP2NC基因片段,并将其连接到原核表达载体pTO-T7,获得重组质粒pTO-T7-CAP2NC,然后转化至大肠杆菌BL21(DE3)菌株,经疏水层析纯化后获得重组蛋白CAP2NC。SDS-PAGE结果表明,重组蛋白CAP2NC可在大肠杆菌可溶高效表达,经纯化后纯度约为95%。ELISA检测表明重组蛋白CAP2NC可被HIV-1衣壳蛋白特异性单克隆抗体识别,具有较好反应活性。重组蛋白透析后在非原性SDS-PAGE中呈现为多种聚体形式。分子筛排阻层析分析CAP2NC蛋白透析后可进行组装,负染电镜进一步观察显示CAP2NC蛋白在RNA存在条件下,可形成空心管状颗粒,其形态结构与HIV-1病毒衣壳体外自组装形成的类似。上述结果表明HIV-1 CAP2NC蛋白具有体外自组装的性质,为进一步在体外研究非成熟病毒样颗粒结构奠定基础。国家自然科学基金(Nos.81671645,81371818)资助~